Description
Quidelortho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing.
Its product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a range of clinical and at-home products to detect COVID-19. The Company’s capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, molecular assay development, lab-based in vitro diagnostics, blood bank solutions and transfusion pre-screening.
Its product categories include visually-read lateral flow, direct fluorescent antibodies, micro-titer production, fluorescent immunoassay products, molecular diagnostic products including its flagship Savanna, immunodiagnostics and integrated testing systems, pre-transfusion testing, immunodiagnostic donor screening systems and services, and ortho care services and informatics.
